SCHEMBL1205600

SCHEMBL1205600

Cc1cc(CC(C)(O)C(=O)O)cc(Cl)c1N

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.33
ADRB1 P08588 4/20 0.33
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
CA12 O43570 1/20 0.32
CA9 Q16790 1/20 0.32
CYP3A4 P08684 4/20 0.32
ADRA1A P35348 2/20 0.32
BLM P54132 2/20 0.32
POLB P06746 2/20 0.32
ALDH1A1 P00352 2/20 0.32
HTT P42858 1/20 0.32
MEN1 O00255 1/20 0.32
USP2 O75604 1/20 0.32
EGFR P00533 1/20 0.32
CYP1A2 P05177 1/20 0.32
FYN P06241 1/20 0.32
GAA P10253 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1205603 1.00 KDM4E (0.33) KDM4EADRB1CA1CA2L3MBTL1
SCHEMBL2165256 0.89 POLB (0.39) KDM4EL3MBTL1CYP3A4ADRA1ABLM
SCHEMBL2165251 0.89 POLB (0.39) KDM4EL3MBTL1CYP3A4ADRA1ABLM
SCHEMBL2163986 0.82 MCL1 (0.40) KDM4EL3MBTL1CYP3A4ADRA1AALDH1A1
SCHEMBL2163990 0.82 MCL1 (0.40) KDM4EL3MBTL1CYP3A4ADRA1AALDH1A1
SCHEMBL1205509 0.81 ADRB2 (0.43) ADRB1MAPTADRB2
SCHEMBL1205511 0.81 ADRB2 (0.43) ADRB1MAPTADRB2
SCHEMBL4510518 0.79 AR (0.35) KDM4EL3MBTL1ADRB2PPARGPPARD
SCHEMBL4510523 0.79 AR (0.35) KDM4EL3MBTL1ADRB2PPARGPPARD
SCHEMBL2165046 0.78 ALDH1A1 (0.43) KDM4ECA1CA2CYP3A4ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110034444-A1 SELECTED CGRP ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-02-10 US disclosed
US-7858622-B2 Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-12-28 US disclosed
US-20100004228-A1 SELECTED CGRP ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-01-07 US disclosed
US-7579341-B2 Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-08-25 US disclosed
US-20070049581-A1 Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004228-A1 SELECTED CGRP ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS CALCRL, CALCR, CALCA KDM4E 4514/4885ADRB1 35/4885CA1 1811/4885
US-20070049581-A1 Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions CALCRL, CALCR, CALCA KDM4E 4514/4885ADRB1 35/4885CA1 1811/4885
US-20110034444-A1 SELECTED CGRP ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS CALCRL, CALCR, CALCA KDM4E 4514/4885ADRB1 35/4885CA1 1811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.